Although asthma has been considered as a single disease for years, recent studies have increasingly focused on its heterogeneity. The characterization of this heterogeneity has promoted the concept that asthma consists of multiple phenotypes or consistent groupings of characteristics. Asthma phenotypes were initially focused on combinations of clinical characteristics, but they are now evolving to link biology to phenotype, often through a statistically based process. Ongoing studies of large-scale, molecularly and genetically focused and extensively clinically characterized cohorts of asthma should enhance our ability to molecularly understand these phenotypes and lead to more targeted and personalized approaches to asthma therapy.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
A plea to abandon asthma as a disease concept. Lancet 368, 705 (2006).
Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258–2261 (1998).
Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261–2263 (1998).
Zhang, D.H. et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 11, 473–482 (1999).
Flood-Page, P. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176, 1062–1071 (2007).
Borish, L.C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816–1823 (1999).
Leckie, M.J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2144–2148 (2000).
Wenzel, S.E. et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 160, 1001–1008 (1999).
Green, R.H. et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360, 1715–1721 (2002).
Green, R.H. et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57, 875–879 (2002).
Jayaram, L. et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J. 27, 483–494 (2006).
Solèr, M. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254–261 (2001).
Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184–190 (2001).
Rackemann, F. A working classification of asthma. Am. J. Med. 3, 601–606 (1947).
Samter, M. & Beers, R.F. Jr. Concerning the nature of intolerance to aspirin. J. Allergy 40, 281–293 (1967).
Merriam-Webster's Collegiate Dictionary 11th edn (Merriam-Webster, Inc., 2008).
Anderson, G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372, 1107–1119 (2008).
Lötvall, J. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 127, 355–360 (2011).
Wenzel, S.E. Asthma: defining of the persistent adult phenotypes. Lancet 368, 804–813 (2006).
Humbert, M. et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am. J. Respir. Crit. Care Med. 154, 1497–1504 (1996).
Humbert, M. et al. High-affinity IgE receptor (FcɛRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am. J. Respir. Crit. Care Med. 153, 1931–1937 (1996).
National Heart, Lung, and Blood Institutes. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (NIH Publication No. 07-4051) (US Department of Health and Human Services, Bethesda, 2007).
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2011. Global Initiative for Asthma <http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html> Ch. 7, 93–132 (2008).
Wenzel, S.E. et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 156, 737–743 (1997).
Miranda, C., Busacker, A., Balzar, S., Trudeau, J. & Wenzel, S.E. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J. Allergy Clin. Immunol. 113, 101–108 (2004).
Pizzichini, M.M. et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur. Respir. J. 13, 15–21 (1999).
Gibson, P.G., Simpson, J.L., Hankin, R., Powell, H. & Henry, R.L. Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax 58, 116–121 (2003).
Haldar, P. et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178, 218–224 (2008).
Moore, W.C. et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 181, 315–323 (2010).
Siroux, V. et al. Identifying adult asthma phenotypes using a clustering approach. Eur. Respir. J. 38, 310–317 (2011).
Fitzpatrick, A.M. et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J. Allergy Clin. Immunol. 127, 382–389.e13 (2011).
Chibana, K. et al. IL-13–induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin. Exp. Allergy 38, 936–946 (2008).
Dweik, R.A. et al. An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. Am. J. Respir. Crit. Care Med. 184, 602–615 (2011).
Fei, M. et al. TNF-α from inflammatory dendritic cells (DCs) regulates lung IL-17A/IL-5 levels and neutrophilia versus eosinophilia during persistent fungal infection. Proc. Natl. Acad. Sci. USA 108, 5360–5365 (2011).
Woodruff, P.G. et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180, 388–395 (2009).
Dougherty, R.H. et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in TH2-high asthma. J. Allergy Clin. Immunol. 125, 1046–1053.e8 (2010).
Hallstrand, T.S., Moody, M.W., Aitken, M.L. & Henderson, W.R. Jr. Airway immunopathology of asthma with exercise-induced bronchoconstriction. J. Allergy Clin. Immunol. 116, 586–593 (2005).
Hallstrand, T.S. et al. Inflammatory basis of exercise-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. 172, 679–686 (2005).
Hallstrand, T.S. et al. Transglutaminase 2, a novel regulator of eicosanoid production in asthma revealed by genome-wide expression profiling of distinct asthma phenotypes. PLoS ONE 5, e8583 (2010).
Szefler, S.J. et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115, 233–242 (2005).
Pearce, N., Douwes, J. & Beasley, R. Is allergen exposure the major primary cause of asthma? Thorax 55, 424–431 (2000).
Phelan, P.D., Robertson, C.F. & Olinsky, A. The Melbourne Asthma Study: 1964–1999. J. Allergy Clin. Immunol. 109, 189–194 (2002).
Gamble, C. et al. Racial differences in biologic predictors of severe asthma: data from the Severe Asthma Research Program. J. Allergy Clin. Immunol. 126, 1149–1156.e1 (2010).
Lajoie, S. et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat. Immunol. 11, 928–935 (2010).
McKinley, L. et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 181, 4089–4097 (2008).
Murdock, B.J. et al. Coevolution of TH1, TH2, and TH17 responses during repeated pulmonary exposure to Aspergillus fumigatus conidia. Infect. Immun. 79, 125–135 (2011).
Moffatt, M.F. et al. A large-scale, consortium-based genome-wide association study of asthma. N. Engl. J. Med. 363, 1211–1221 (2010).
Bisgaard, H. et al. Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. Am. J. Respir. Crit. Care Med. 179, 179–185 (2009).
Slager, R.E. et al. Predictive model of severe atopic asthma phenotypes using interleukin-4/13 pathway polymorphisms. Am. J. Respir. Crit. Care Med. 183, A1332 (2011).
Wu, C.Y., Fargeas, C., Nakajima, T. & Delespesse, G. Glucocorticoids suppress the production of interleukin-4 by human lymphocytes. Eur. J. Immunol. 21, 2645–2647 (1991).
Kunicka, J.E. et al. Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell. Immunol. 149, 39–49 (1993).
Maneechotesuwan, K. et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med. 6, e1000076 (2009).
Berry, M. et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 62, 1043–1049 (2007).
Djukanović, R. et al. Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am. Rev. Respir. Dis. 142, 863–871 (1990).
Djukanović, R. et al. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am. J. Respir. Crit. Care Med. 155, 826–832 (1997).
Fahy, J.V. et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 155, 1828–1834 (1997).
Gauvreau, G.M. et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med. 183, 1007–1014 (2011).
Wenzel, S., Wilbraham, D., Fuller, R., Getz, E.B. & Longphre, M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422–1431 (2007).
Slager, R.E. et al. IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J. Allergy Clin. Immunol. 126, 875–878 (2010).
Hanania, N.A. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 154, 573–582 (2011).
Humbert, M., Berger, W., Rapatz, G. & Turk, F. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy 63, 592–596 (2008).
Busse, W.W. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 364, 1005–1015 (2011).
Fitzpatrick, A.M., Gaston, B.M., Erzurum, S.C. & Teague, W.G. Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide. J. Allergy Clin. Immunol. 118, 1218–1225 (2006).
Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088–1098 (2011).
Arron, J. et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 183, A4455 (2011).
Scheerens, H. et al. Predictive and pharmacodynamic biomarkers of interleukin-13 blockade: effect of lebrikizumab on late-phase asthmatic response to allergen challenge. J. Allergy Clin. Immunol. 127, AB164 (2011).
Saha, S.K. et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J. Allergy Clin. Immunol. 121, 685–691 (2008).
Chibana, K. et al. Balance of inducible nitric oxide synthase and arginase 2 in bronchial epithelial cells from asthmatic subjects predicts asthma severity: Symptoms and inflammatory processes. Am. J. Respir. Crit. Care Med. 177, A975 (2008).
Kharitonov, S.A. & Barnes, P.J. Nitric oxide in exhaled air is a new marker of airway inflammation. Monaldi Arch. Chest Dis. 51, 533–537 (1996).
Belda, J. et al. Induced sputum cell counts in healthy adults. Am. J. Respir. Crit. Care Med. 161, 475–478 (2000).
Spanevello, A. et al. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am. J. Respir. Crit. Care Med. 162, 1172–1174 (2000).
van Veen, I.H. et al. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J. Allergy Clin. Immunol. 124, 615–617.e2 (2009).
Heller, F. et al. Interleukin-13 is the key effector TH2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550–564 (2005).
Hoshino, T. et al. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am. J. Respir. Crit. Care Med. 176, 49–62 (2007).
Tepper, R.I., Coffman, R.L. & Leder, P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257, 548–551 (1992).
Hastie, A.T. et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J. Allergy Clin. Immunol. 125, 1028–1036.e13 (2010).
Eiwegger, T. & Akdis, C.A. IL-33 links tissue cells, dendritic cells and TH2 cell development in a mouse model of asthma. Eur. J. Immunol. 41, 1535–1538 (2011).
Doe, C. et al. Expression of the T helper 17–associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 138, 1140–1147 (2010).
Shannon, J. et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 133, 420–426 (2008).
Cowburn, A.S. et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 101, 834–846 (1998).
Christie, P.E. et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143, 1025–1029 (1991).
Sanak, M., Simon, H.U. & Szczeklik, A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350, 1599–1600 (1997).
Choi, J.H. et al. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum. Genet. 114, 337–344 (2004).
Bachert, C., Wagenmann, M., Hauser, U. & Rudack, C. IL-5 synthesis is upregulated in human nasal polyp tissue. J. Allergy Clin. Immunol. 99, 837–842 (1997).
Sánchez-Segura, A., Brieva, J.A. & Rodriguez, C. T lymphocytes that infiltrate nasal polyps have a specialized phenotype and produce a mixed TH1/TH2 pattern of cytokines. J. Allergy Clin. Immunol. 102, 953–960 (1998).
Stankovic, K.M., Goldsztein, H., Reh, D.D., Platt, M.P. & Metson, R. Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. Laryngoscope 118, 881–889 (2008).
Chu, H.W. et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin. Exp. Allergy 32, 1558–1565 (2002).
Yamamoto, M. et al. Nitric oxide and related enzymes in asthma: Relation to severity, enzyme function and inflammation. Clin. Exp. Allergy doi: 10.1111/j.1365-2222.2011.03860.x (2011).
Stirling, R.G. et al. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group. Thorax 53, 1030–1034 (1998).
Haldar, P. et al. Mepolizumab (anti–IL-5) and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973–984 (2009).
Schleimer, R.P. & Bochner, B.S. The effects of glucocorticoids on human eosinophils. J. Allergy Clin. Immunol. 94, 1202–1213 (1994).
Woolley, K.L. et al. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 154, 237–243 (1996).
ten Brinke, A., Zwinderman, A.H., Sterk, P.J., Rabe, K.F. & Bel, E.H. “Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am. J. Respir. Crit. Care Med. 170, 601–605 (2004).
Dahlén, B. et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am. J. Respir. Crit. Care Med. 157, 1187–1194 (1998).
Dahlén, S.E. et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165, 9–14 (2002).
Nair, P. et al. Mepolizumab in prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360, 985–993 (2009).
Wenzel, S. et al. A phase 2b study of inhaled pitrakinra, an IL-4/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma. Am. J. Respir. Crit. Care Med. 183, A19045 (2011).
Helenius, I.J., Tikkanen, H.O., Sarna, S. & Haahtela, T. Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event as risk factors. J. Allergy Clin. Immunol. 101, 646–652 (1998).
Karjalainen, E.M. et al. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am. J. Respir. Crit. Care Med. 161, 2086–2091 (2000).
Finnerty, J.P., Wood-Baker, R., Thomson, H. & Holgate, S.T. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am. Rev. Respir. Dis. 145, 746–749 (1992).
Reiss, T.F. et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 52, 1030–1035 (1997).
Parker, J.M. et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti–interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm. Med. 11, 14 (2011).
Bisgaard, H. & Bønnelykke, K. Long-term studies of the natural history of asthma in childhood. J. Allergy Clin. Immunol. 126, 187–197 (2010).
Martin, P.E. et al. Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: a prospective cohort study over 4 decades. J. Allergy Clin. Immunol. 127, 1473–1479.e1 (2011).
Corren, J. et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am. J. Respir. Crit. Care Med. 181, 788–796 (2010).
Kim, H.Y., DeKruyff, R.H. & Umetsu, D.T. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat. Immunol. 11, 577–584 (2010).
Black, J.L. & Roth, M. Intrinsic asthma: is it intrinsic to the smooth muscle? Clin. Exp. Allergy 39, 962–965 (2009).
Li, X. et al. Importance of hedgehog interacting protein and other lung function genes in asthma. J. Allergy Clin. Immunol. 127, 1457–1465 (2011).
van Diemen, C.C. et al. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am. J. Respir. Crit. Care Med. 172, 329–333 (2005).
Brightling, C.E. et al. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am. J. Respir. Crit. Care Med. 171, 1103–1108 (2005).
Yu, M. et al. Identification of an IFN-γ/mast cell axis in a mouse model of chronic asthma. J. Clin. Invest. 121, 3133–3143 (2011).
Locke, G.R. III, Talley, N.J., Fett, S.L., Zinsmeister, A.R. & Melton, L.J. III Risk factors associated with symptoms of gastroesophageal reflux. Am. J. Med. 106, 642–649 (1999).
Nilsson, M., Johnsen, R., Ye, W., Hveem, K. & Lagergren, J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. J. Am. Med. Assoc. 290, 66–72 (2003).
Sin, D.D., Jones, R.L. & Man, S.F. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch. Intern. Med. 162, 1477–1481 (2002).
Pakhale, S. et al. A comparison of obese and nonobese people with asthma: exploring an asthma-obesity interaction. Chest 137, 1316–1323 (2010).
Hotamisligil, G.S., Shargill, N.S. & Spiegelman, B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259, 87–91 (1993).
Loffreda, S. et al. Leptin regulates proinflammatory immune responses. FASEB J. 12, 57–65 (1998).
Komakula, S. et al. Body mass index is associated with reduced exhaled nitric oxide and higher exhaled 8-isoprostanes in asthmatics. Respir. Res. 8, 32 (2007).
Peters-Golden, M. et al. Influence of body mass index on the response to asthma controller agents. Eur. Respir. J. 27, 495–503 (2006).
Dixon, A.E. et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J. Allergy Clin. Immunol. 128, 508–515.e2 (2011).
Holguin, F. et al. Obesity and asthma: an association modified by age of asthma onset. J. Allergy Clin. Immunol. 127, 1486–1493.e2 (2011).
Reddy, R.C., Baptist, A.P., Fan, Z., Carlin, A.M. & Birkmeyer, N.J. The effects of bariatric surgery on asthma severity. Obes. Surg. 21, 200–206 (2011).
Lugogo, N.L., Kraft, M. & Dixon, A.E. Does obesity produce a distinct asthma phenotype? J. Appl. Physiol. 108, 729–734 (2010).
Jatakanon, A. et al. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. 160, 1532–1539 (1999).
Schleimer, R.P., Freeland, H.S., Peters, S.P., Brown, K.E. & Derse, C.P. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J. Pharmacol. Exp. Ther. 250, 598–605 (1989).
Kato, T., Takeda, Y., Nakada, T. & Sendo, F. Inhibition by dexamethasone of human neutrophil apoptosis in vitro. Nat. Immun. 14, 198–208 (1995).
Woodruff, P.G. et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J. Allergy Clin. Immunol. 108, 753–758 (2001).
Busacker, A. et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 135, 48–56 (2009).
Gupta, S. et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 136, 1521–1528 (2009).
Vignola, A.M. et al. Increased levels of elastase and α1-antitrypsin in sputum of asthmatic patients. Am. J. Respir. Crit. Care Med. 157, 505–511 (1998).
Simpson, J.L., Scott, R.J., Boyle, M.J. & Gibson, P.G. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am. J. Respir. Crit. Care Med. 172, 559–565 (2005).
Cowan, D.C., Cowan, J.O., Palmay, R., Williamson, A. & Taylor, D.R. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 65, 384–390 (2010).
Baines, K.J., Simpson, J.L., Wood, L.G., Scott, R.J. & Gibson, P.G. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J. Allergy Clin. Immunol. 127, 153–160.e9 (2011).
Bourgeois, E.A. et al. A natural protective function of invariant NKT cells in a mouse model of innate-cell-driven lung inflammation. Eur. J. Immunol. 41, 299–305 (2011).
Simpson, J.L., Powell, H., Boyle, M.J., Scott, R.J. & Gibson, P.G. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am. J. Respir. Crit. Care Med. 177, 148–155 (2008).
Wenzel, S.E. et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med. 179, 549–558 (2009).
Chakir, J. et al. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression. J. Allergy Clin. Immunol. 111, 1293–1298 (2003).
Holt, P.G. & Sly, P.D. Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. Chest 139, 1165–1171 (2011).
Thomson, N.C. & Chaudhuri, R. Asthma in smokers: challenges and opportunities. Curr. Opin. Pulm. Med. 15, 39–45 (2009).
van den Berge, M., Heijink, H.I., van Oosterhout, A.J. & Postma, D.S. The role of female sex hormones in the development and severity of allergic and non-allergic asthma. Clin. Exp. Allergy 39, 1477–1481 (2009).
Singh, A.M., Moore, P.E., Gern, J.E., Lemanske, R.F. Jr. & Hartert, T.V. Bronchiolitis to asthma: a review and call for studies of gene–virus interactions in asthma causation. Am. J. Respir. Crit. Care Med. 175, 108–119 (2007).
Gern, J.E. The ABCs of rhinoviruses, wheezing, and asthma. J. Virol. 84, 7418–7426 (2010).
Maestrelli, P., Boschetto, P., Fabbri, L.M. & Mapp, C.E. Mechanisms of occupational asthma. J. Allergy Clin. Immunol. 123, 531–542 (2009).
The author thanks F. Holguin and P. Woodruff for their thoughtful review of this manuscript.
The author declares no competing financial interests.
About this article
Cite this article
Wenzel, S. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18, 716–725 (2012). https://doi.org/10.1038/nm.2678
Pharmacological Research (2020)
Pharmacological Research (2020)
Journal of Asthma (2020)
Immunology and Allergy Clinics of North America (2020)
Expert Review of Respiratory Medicine (2020)